In a study of stage IV non-small cell lung cancer treated before and during Lebanon's immunotherapy shortage, 56% of patients given immunotherapy received reduced doses; progression-free survival did not differ significantly from before the crisis, in a study not designed to prove equivalence.
Published as "Impact of Lack of Access to Immunotherapy on Survival in Stage IV Non-Small Cell Lung Cancer: A Multicenter Retrospective Study From Lebanon". The authors, at the Naef K. Basile Cancer Institute of the American University of Beirut Medical Center and other centres, compared patients treated from January 2019 to December 2020 with those treated from October 2021 to December 2022, when the economic collapse caused shortages and interruptions of immunotherapy.
Records how Lebanese oncologists stretched scarce immunotherapy during the shortage; the authors caution that the study cannot show reduced doses work as well.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/